Aislinn Antrim, Managing Editor

The efficacy and tolerability of rizatriptan for acute migraine treatment has been well established.

Respiratory syncytial virus (RSV) vaccine demonstrated efficacy of 66.7% in reducing RSV-associated lower respiratory tract illness with at least 2 signs or symptoms in older adults.

Based on the study results, investigators concluded that there is justification for a randomized clinical trial.

The risk of a second stroke after intracerebral hemorrhage (ICH) did not differ by index hematoma location, and this risk was higher for ischemic stroke than ICH.

During the 12-month trial period, Hyqvia was shown to be efficacious treating the occurrence of acute serious bacterial infections in children aged 2 through 16 years with primary immunodeficiency.

Availability of clinical trials in the gynecologic cancer care space are increasing, but it is important to be mindful of current racial disparities.

The risk is particularly high in the first 2 years after an HIV diagnosis.

It is still unclear whether comorbidities have similar negative effects on cognition beyond those directly caused by obstructive sleep apnea.

Taken together, the studies point to meaningful changes in the standard of care for patients with advanced or recurrent endometrial cancer.

The trial did not meet the second primary efficacy endpoint of medically attended respiratory syncytial virus-associated lower respiratory tract illness.

The overall survival hazard ratio numerically favored niraparib in the germline BRCA mutation cohort and favored placebo in the non-germline BRCA mutation cohort in patients with platinum-sensitive recurrent ovarian cancer.

Among those without HIV, the analyses found that respondents with a history of COVID-19 performed worse on processing speed than those who had never had COVID-19.

The application is based on the PHAROS trial, which met its primary endpoint of objective response rate in patients with metastatic non–small cell lung cancer with a BRAF V600E mutation.

Students still have a myriad of career options, including at retail pharmacies, hospitals, and outside traditional practice.

Improvements in progression-free survival were seen in patients with advanced or recurrent endometrial carcinoma regardless of mismatch repair status.

Key lifestyle risk factors for chronic diseases and cancers include tobacco use, poor nutrition, lack of physical movement, and obesity.

Presenter at the 2023 Community Oncology Alliance meeting notes that oncology has become more of a duality between molecular and genetic subsets, leading to huge developments in targeted and personalized care.

Among patients with lung cancer, approximately 20% have the earliest stage of disease but are still dying of metastatic lung cancer within about 5 years.

Drugs such as pembrolizumab, sacituzumab govitecan, and datopotamab deruxtecan all have growing bodies of evidence illustrating which patients with cancer are most likely to benefit and in which settings.

Despite tensions that can occur, building relationships with health systems and finding opportunities to collaborate is crucial to improve cancer care.

Sandoz intends to launch the latest Humira biosimilar in the United States on July 1, 2023.

The kit is now approved in the US to select patients with metastatic prostate cancer who are candidates for the only FDA-approved PSMA-directed radioligand therapy.

Liquid formulations of dabrafenib plus trametinib were also approved, marking the first time a BRAF/MEK inhibitor has been developed in a formulation suitable for patients as young as 1 year of age.

At 1 year, patients receiving chemotherapy regimens containing anthracyclines for lymphoma who took statins had an average ejection fraction that was 1.3% higher than those who took placebo.

Among the participants who were initially unsure or hesitant about vaccination, 82% received flu and Tdap vaccines during pregnancy after the online intervention.

Osimertinib (Tagrisso; AstraZeneca) now has shown a statistically significant and clinically meaningful overall survival benefit in both the early adjuvant and late-stage metastatic settings.

The fourth dose of the bivalent vaccine elicited improved Omicron BA.4/BA.5-neutralizing antibody responses compared to participants who received 3 doses of the original vaccine.

Adding durvalumab to neoadjuvant chemotherapy to treat resectable early-stage non–small cell lung cancer did not increase complications and adverse events or comprise patients’ ability to undergo surgery versus chemotherapy alone.

Trofinetide is the first and only drug approved for the treatment of Rett syndrome.

The KEYNOTE-641 and -789 trials did not demonstrate improvements or meet the primary endpoints in metastatic castration-resistant prostate cancer and metastatic nonsquamous non–small cell lung cancer.